We are live on ! Find out more
VINC

Vincerx Pharma, Inc. Common Stock
VINC

Delisted

VINC was delisted on the 22nd of April, 2025.

Back to rankings

51 hedge funds and large institutions have $18.4M invested in Vincerx Pharma, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 15

24% less funds holding

Funds holding: 67 → 51 (-16)

64% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 22

72% less capital invested

Capital invested by funds: $65.1M → $18.4M (-$46.7M)

Holders
51
Holders Change
-16
Holders Change %
-23.88%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
15
Reduced
15
Closed
22
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LFCM
Long Focus Capital Management
Puerto Rico
+$1.22M
2
Millennium Management
Millennium Management
New York
+$579K
3
SM
Sabby Management
Florida
+$385K
4
Renaissance Technologies
Renaissance Technologies
New York
+$380K
5
ECM
ExodusPoint Capital Management
New York
+$223K

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$5.52M
2
SFM
Sphera Funds Management
Israel
-$1.44M
3
BlackRock
BlackRock
New York
-$1.4M
4
Russell Investments Group
Russell Investments Group
United Kingdom
-$906K
5
State Street
State Street
Massachusetts
-$348K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCMNY
1
Rubric Capital Management (New York)
New York
$2.78M – – –
SRC
2
Sage Rhino Capital
California
$2.19M +$88.9K +2,000 +2%
AAA
3
Affinity Asset Advisors
New York
$1.81M – – –
TCM
4
Tang Capital Management
California
$1.36M – – –
LFCM
5
Long Focus Capital Management
Puerto Rico
$1.29M +$1.22M +27,490 +128%
RSCM
6
Rock Springs Capital Management
Maryland
$1.07M – – –
Holocene Advisors
7
Holocene Advisors
New York
$1M – – –
Citadel Advisors
8
Citadel Advisors
Florida
$824K -$1.02K -23 -0.1%
Vanguard Group
9
Vanguard Group
Pennsylvania
$765K -$193K -4,330 -13%
SM
10
Sabby Management
Florida
$661K +$385K +8,666 +53%
CC
11
Clearline Capital
New York
$597K +$87.9K +1,976 +10%
KCM
12
Kingdon Capital Management
New York
$508K – – –
Point72 Asset Management
13
Point72 Asset Management
Connecticut
$455K – – –
Renaissance Technologies
14
Renaissance Technologies
New York
$413K +$380K +8,539 +120%
Millennium Management
15
Millennium Management
New York
$405K +$579K +13,016 +562%
SSA
16
Schonfeld Strategic Advisors
New York
$387K +$63.4K +1,426 +11%
BBA
17
Baker Bros. Advisors
New York
$319K – – –
BlackRock
18
BlackRock
New York
$188K -$1.4M -31,431 -82%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$181K -$294K -6,611 -49%
PVI
20
Pura Vida Investments
New York
$143K – – –
SCM
21
Sio Capital Management
New York
$135K – – –
ECM
22
ExodusPoint Capital Management
New York
$132K +$223K +5,005 New
E
23
Ergoteles
New York
$107K +$179K +4,035 New
SFM
24
Sphera Funds Management
Israel
$93K -$1.44M -32,485 -90%
LP
25
LMR Partners
United Kingdom
$83K +$26.1K +587 +23%
1
2 3

VINC Hedge Fund Activity: Q2 2022 in Review

51 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q2 2022, worth a combined $18.4M — down 72% from $65.1M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of VINC and 8 opened new positions — a net loss of 14 holders — while 15 trimmed existing stakes and 15 added.

The largest buyer was Long Focus Capital Management, adding an estimated $1.22M. The largest seller was Deerfield Management, exiting entirely with an estimated $5.52M sold.

  • 51 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q2 2022, down from 67 in Q1 2022.
  • Funds reported $18.4M of Vincerx Pharma, Inc. Common Stock stock for Q2 2022, down 72% quarter-over-quarter.
  • 8 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q2 2022 and 22 closed out, a net change of -14 holders.
  • The largest Vincerx Pharma, Inc. Common Stock buyer in Q2 2022 was Long Focus Capital Management, an estimated $1.22M added.
  • The largest Vincerx Pharma, Inc. Common Stock seller in Q2 2022 was Deerfield Management, an estimated $5.52M sold.

Based on aggregated 13F filings for Q2 2022.